ClinicalTrials.gg
CompletedNCT04966689Updated Apr 4, 2023

The Effect of Combined Speech and Music-therapy on the Speech Characteristics of People With Parkinson's Disease (PD)

An interventional study of combined speech and music therapy and speech therapy in Speech Disorders, Voice Disorders and Parkinson Disease, sponsored by Iran University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-04.

Sponsored by Iran University of Medical Sciences · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Speech and voice disorders are observed in almost 90% of patients with PD during their course of illness. Reduced voice pitch inflections or monotone speech, reduced vocal loudness, prosody disorders, the imprecise articulation of the consonants, hoarseness, and breathy voice is also observed in patients with PD; these symptoms often lead to reduced speech intelligibility. The aim of this study will to investigate the possible changes in the voice and speech features in people with PD after a combined speech and music therapy using Telerehabilitation.

Read the detailed description

the investigators of this study propose to conduct a pilot randomized, controlled trial in patients with PD to assess the potential effectiveness of a Telerehabilitation intervention that encourage a higher level of speech performance. The investigators hypothesize that patients in the combined treatment group will have more and better improve in the study outcome measures after treatment and 3 month follow up, as compared with patients in speech therapy group and music therapy group.

02

Conditions studied

  • Speech Disorders
  • Voice Disorders
  • Parkinson Disease
03

In context

Speech Disorders

77 studies on the registry are indexed under Speech Disorders; 20 are open to participants now.

This study's enrollment of 33 is below the median of 38 across 54 interventional studies indexed under Speech Disorders.

Browse Speech Disorders studies →

Lead sponsor

Iran University of Medical Sciences is the lead sponsor of 25 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with idiopathic Parkinson's disease (IPD)
  • Patients who are in stages 1-3 according to Hoehn \& Yahr test
  • Native language is persian
  • The patient or family complains about the person's speech condition
  • Adequate vision and hearing
  • No history of stroke, head injury, brain surgery, laryngeal diseases such as vocal cord nodules
  • No other neurological disorders other than IPD
  • Do not use treatment other than medication (such as deep brain stimulation surgery (DBS)

Exclusion criteria

Exclusion Criteria:

  • If a patient develops a stroke or other neurological complication during treatment, they are excluded from the treatment
  • Lack of cooperation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    combined speech and music therapy

    the telerehabilitation intervention that include both speech therapy and music therapy at the same time

    Behavioral: combined speech and music therapy

  • Active comparator
    speech therapy

    A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation

    Behavioral: speech therapy

  • Active comparator
    music therapy

    music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation

    Behavioral: music therapy

Interventions

  • Behavioralcombined speech and music therapy

    he telerehabilitation intervention that include both speech therapy and music therapy at the same time

  • Behavioralspeech therapy

    A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation

  • Behavioralmusic therapy

    music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation

06

What researchers measure

Primary outcomes

  1. loudness

    Change in loudness over the period of the study which will be based on analysis of acoustic recordings. Loudness of voice will be measured in produce the vowel /a /, reading and spontaneous speech. Data will be analyzed using Praat, freeware program for the analysis and reconstruction of acoustic speech signals.

    Time frame: Change from Baseline in loudness at 4 weeks and 3 month follow up

Secondary outcomes

  1. Voice Handicap Index (VHI)

    Change in Persian version of Voice Handicap Index (VHI) over the period of the study. The VHI measures the influence of voice problems on a patient's quality of life. The VHI is a 30 item scale. The total scores range is 0-120. A score 60-120 indicates severe voice problem.

    Time frame: Change from Baseline in VHI at 4 weeks and 3 month follow up

  2. maximum phonation time (MPT)

    Change in maximum phonation time (MPT) over the period of the study. MPT will be measured by asking the subject to produce the long vowel /a/. This vocalization is measured three times, and the longest MPT is recorded.

    Time frame: Change from Baseline in MPT at 4 weeks and 3 month follow up

  3. Speech Intelligibility

    Change in fudalla speech intelligibility rating scale over the period of the study. This scale consists of 7 rates in which the number 1 indicates Speech is not intelligible and number 7 indicates Speech is totally intelligible.

    Time frame: Change from Baseline in Speech Intelligibility at 4 weeks and 3 month follow up

  4. Swallowing Disturbance Questionnaire (SDQ)

    Change in Persian version of Swallowing Disturbance Questionnaire (SDQ) over the period of the study. The SDQ is a 15 item scale. The total scores range is 0-45. A score higher 11 indicates swallowing difficulty.

    Time frame: Change from Baseline in SDQ at 4 weeks and 3 month follow up

  5. Dysphagia handicap index (DHI)

    Change in Persian version of Dysphagia handicap index (DHI) over the period of the study. The DHI is one of the instruments used for measuring a dysphagic patient's self-assessment. it reflects the patient's quality of life. DHI is a 25 item scale. The total scores range is 0-100. A higher score indicates a greater impact of swallowing disorders on quality of life

    Time frame: Change from Baseline in DHI at 4 weeks and 3 month follow up

  6. northwest dysphagia patient check sheet (NDPCS)

    Change in Persian version of northwest dysphagia patient check sheet (NPCS) scores over the period of the study. The NDPCS has five and 28 items. Each item is scored as safe or unsafe. The total score is calculated from the total number of unsafe items. The more unsafe observations indicates swallowing difficulty.

    Time frame: Change from Baseline in NDPCS at 4 weeks and 3 month follow up

  7. Geriatric Depressive Scale (GDS)

    Change in Persian version of Geriatric Depressive Scale (GDS) scores over the period of the study. GDS is a 15 item scale. Each item is scored as yes or no. More than 5 signs indicate the possibility of depression and more than 10 signs of depression indicate definite depression.

    Time frame: Change from Baseline in GDS at 4 weeks and 3 month follow up

  8. quality of life (QoL)

    Change in SF-36 questionnaire over the period of the study. Quality of life will be measured using SF-36 questionnaire. SF-36 is a 36 item scale. The total scores range is 0-100. A higher score indicates a better quality of life.

    Time frame: Change from Baseline in QOL at 4 weeks and 3 month follow up

  9. jitter

    Change in jitter over the period of the study, which will be based on analysis of acoustic recordings. jitter will be measured in produce the vowel /a/. Data will be analyzed using Praat, freeware program for the analysis and reconstruction of acoustic speech signals.

    Time frame: Change from Baseline in jitter at 4 weeks and 3 month follow up

  10. shimmer

    Change in shimmer over the period of the study, which will be based on analysis of acoustic recordings. shimmer will be measured in produce the vowel /a/. Data will be analyzed using Praat, freeware program for the analysis and reconstruction of acoustic speech signals.

    Time frame: Change from Baseline in shimmer at 4 weeks and 3 month follow up

  11. highest and lowest frequency

    Change in highest and lowest frequency over the period of the study, which will be based on analysis of acoustic recordings. highest and lowest frequency will be measured by asking the subject to produce the vowel /a/ as high and low frequency as they can produces. Data will be analyzed using Praat, freeware program for the analysis and reconstruction of acoustic speech signals.

    Time frame: Change from highest and lowest frequency at 4 weeks and 3 month follow up

07

Study locations

1 site
  • Iran University of Medical Sciences
    Tehran, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jan 2022, 5 months.

Of 35 non-industry interventional studies with no phase under Speech Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 38. This study's 5 months is below that.

Counting every sponsor, half of 37 studies reached it within 28 months; a quarter within 17 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Jul 19, 2021
StartActual
Jul 17, 2021
Primary completionActual
Jan 7, 2022
CompletionActual
Jan 30, 2022
Last update
Apr 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04966689
Lead sponsor
Iran University of Medical Sciences
Responsible party
Sponsor
First posted
Jul 19, 2021
Start date
Jul 17, 2021
Primary completion
Jan 7, 2022
Completion
Jan 30, 2022
Last update
Apr 4, 2023

Study contacts

Reyhaneh Mohammadi
study director · Iran university of medical science

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion